These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26172561)

  • 1. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
    Hillarp A; Friedman KD; Adcock-Funk D; Tiefenbacher S; Nichols WL; Chen D; Stadler M; Schwartz BA
    Haemophilia; 2015 Nov; 21(6):837-45. PubMed ID: 26172561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.
    de Maistre E; Volot F; Mourey G; Aho LS; Ternisien C; Briquel ME; Bertrand MA; Tardy B; Frotscher B; Nguyen P; Dumont L; Vandroux D; Hézard N; Trossaërt M
    Thromb Haemost; 2014 Oct; 112(4):825-30. PubMed ID: 25103956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin.
    Patzke J; Budde U; Huber A; Méndez A; Muth H; Obser T; Peerschke E; Wilkens M; Schneppenheim R
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):860-70. PubMed ID: 25192242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
    Hayward CP; Moffat KA; Graf L
    Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000).
    Lattuada A; Preda L; Sacchi E; Gallo L; Federici AB; Rossi E
    Blood Coagul Fibrinolysis; 2004 Sep; 15(6):505-11. PubMed ID: 15311161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
    Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
    J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.
    Cabrera N; Moret A; Caunedo P; Cid AR; Vila V; España F; Aznar JA
    Haemophilia; 2013 Nov; 19(6):920-5. PubMed ID: 23730809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol.
    Hillarp A; Stadler M; Haderer C; Weinberger J; Kessler CM; Römisch J
    J Thromb Haemost; 2010 Oct; 8(10):2216-23. PubMed ID: 20727070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
    Verfaillie CJ; De Witte E; Devreese KM
    Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry.
    Chen D; Daigh CA; Hendricksen JI; Pruthi RK; Nichols WL; Heit JA; Owen WG
    J Thromb Haemost; 2008 Feb; 6(2):323-30. PubMed ID: 18031294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.